Abstract
Purpose :
To apply M-CHARTS for quantitative measurements of metamorphopsia in eyes with acute branch retinal vein occlusion (BRVO) and to elucidate the pathomorphology that causes metamorphopsia.
Methods :
This prospective study consisted of 42 consecutive patients (42 eyes) with acute BRVO. Both at baseline and one month after the treatment with ranibizumab, metamorphopsia was measured with M-CHARTS, and the retinal morphological changes were examined with optical coherence tomography.
Results :
At baseline, metamorphopsia was detected in the vertical and/or horizontal directions in 29 (69.0%) eyes; the mean vertical and horizontal scores were 0.59 ± 0.57 and 0.52 ± 0.67, respectively. The maximum inner retinal thickness showed no association with the M-CHARTS score, but the M-CHARTS score was correlated with the total foveal thickness (r = 0.43, P = .004), the height of serous retinal detachment (r = 0.31, P = .047), and the maximum outer retinal thickness (r = 0.36, P = .020). One month after treatment, both the inner and outer retinal thickness substantially decreased in all eyes. However, metamorphopsia persisted in 26 (89.7%) of 29 eyes. The posttreatment M-CHARTS score was not correlated with any posttreatment morphological parameters. However, the posttreatment M-CHARTS score was weakly correlated with the baseline total foveal thickness (r = 0.35. P = .024) and closely correlated with the baseline M-CHARTS score (r = 0.78, P < .001).
Conclusions :
Metamorphopsia associated with acute BRVO was quantified using M-CHARTS.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.